|
WO1986005779A1
(en)
|
1985-04-03 |
1986-10-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Phenylene derivatives
|
|
US5192553A
(en)
|
1987-11-12 |
1993-03-09 |
Biocyte Corporation |
Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5273986A
(en)
|
1992-07-02 |
1993-12-28 |
Hoffmann-La Roche Inc. |
Cycloalkylthiazoles
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
US6143780A
(en)
|
1999-09-17 |
2000-11-07 |
Uniroyal Chemical Company, Inc. |
N-arylmethylthioanilide compounds useful for the inhibition of the replication of HIV
|
|
US6887870B1
(en)
|
1999-10-12 |
2005-05-03 |
Bristol-Myers Squibb Company |
Heterocyclic sodium/proton exchange inhibitors and method
|
|
EP1227321A1
(en)
*
|
2000-12-28 |
2002-07-31 |
Institut für Bioanalytik GmbH |
Reversible MHC multimer staining for functional purification of antigen-specific T cells
|
|
CA2437248A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
US20060063782A1
(en)
|
2002-07-03 |
2006-03-23 |
Murray Christopher W |
3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
|
|
WO2004099388A2
(en)
|
2003-03-05 |
2004-11-18 |
Proteologics, Inc. |
Cbl-b polypeptides, complexes and related methods
|
|
US7320992B2
(en)
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
|
WO2005080367A1
(en)
|
2004-02-12 |
2005-09-01 |
Pharmagene Laboratories Limited |
Ep2 receptor agonists
|
|
CN101365806B
(zh)
|
2005-12-01 |
2016-11-16 |
医学预后研究所 |
用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
|
|
JP5113348B2
(ja)
*
|
2006-05-25 |
2013-01-09 |
国立大学法人徳島大学 |
ユビキチンリガーゼ阻害剤
|
|
ES2566502T3
(es)
|
2006-09-13 |
2016-04-13 |
The Trustees Of Columbia University In The City Of New York |
Agentes y métodos para provocar una respuesta inmune antitumoral
|
|
CA2704266A1
(en)
*
|
2007-11-02 |
2009-06-11 |
Vertex Pharmaceuticals Incorporated |
[1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
|
|
AT506041A1
(de)
|
2007-12-10 |
2009-05-15 |
Univ Innsbruck |
Verfahren zur erhöhung der immunreaktivität
|
|
CA2710462C
(en)
|
2008-02-05 |
2015-11-24 |
F. Hoffmann-La Roche Ag |
Pyridinones and pyridazinones
|
|
AR079545A1
(es)
|
2009-12-21 |
2012-02-01 |
Bayer Cropscience Ag |
Tienilpiri(mi)dinilazol
|
|
KR101862327B1
(ko)
|
2010-05-07 |
2018-05-29 |
질레드 코네티컷 인코포레이티드 |
피리돈 및 아자-피리돈 화합물 및 사용 방법
|
|
MX342995B
(es)
|
2010-07-13 |
2016-10-21 |
Anthrogenesis Corp |
Métodos de generar células asesinas naturales.
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
EP2471548A1
(de)
*
|
2010-12-28 |
2012-07-04 |
Apeiron Biologics AG |
siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
|
|
WO2012175513A1
(en)
|
2011-06-20 |
2012-12-27 |
Bayer Intellectual Property Gmbh |
Thienylpyri(mi)dinylpyrazole
|
|
WO2013067264A1
(en)
|
2011-11-03 |
2013-05-10 |
Genentech, Inc. |
8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
KR20150054994A
(ko)
|
2012-09-13 |
2015-05-20 |
에프. 호프만-라 로슈 아게 |
브루톤 티로신 키나아제의 억제제
|
|
EP3008052A1
(en)
|
2013-06-13 |
2016-04-20 |
Bristol-Myers Squibb Company |
Macrocyclic factor viia inhibitors
|
|
CA2921199A1
(en)
|
2013-08-27 |
2015-03-05 |
Bristol-Myers Squibb Company |
Ido inhibitors
|
|
US10308707B2
(en)
|
2013-12-02 |
2019-06-04 |
Aaron Diamond Aids Research Center |
Bispecific HIV-1-neutralizing antibodies
|
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
RU2763795C2
(ru)
|
2014-04-23 |
2022-01-11 |
Джуно Терапьютикс, Инк. |
Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
|
|
AU2015289644A1
(en)
*
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
BR112017025986A2
(pt)
|
2015-06-02 |
2018-08-14 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton.
|
|
EP3325475B1
(en)
|
2015-07-17 |
2020-03-18 |
Takeda Pharmaceutical Company Limited |
Oxadiazole derivatives useful as hdac inhibitors
|
|
EP3138905A1
(en)
|
2015-09-04 |
2017-03-08 |
Miltenyi Biotec GmbH |
Method for natural killer cell expansion
|
|
CN108884140B
(zh)
|
2015-12-03 |
2022-10-25 |
朱诺治疗学股份有限公司 |
修饰的嵌合受体及相关组合物和方法
|
|
WO2017107907A1
(zh)
|
2015-12-25 |
2017-06-29 |
四川海思科制药有限公司 |
稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用
|
|
EP3254701A1
(en)
|
2016-06-09 |
2017-12-13 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
|
|
US10842878B2
(en)
|
2016-11-22 |
2020-11-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
EP3630291B9
(en)
*
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
|
WO2019063748A1
(en)
|
2017-09-30 |
2019-04-04 |
Glaxosmithkline Intellectual Property Development Limited |
INHIBITORS OF ROR-GAMMA
|
|
WO2019148005A1
(en)
|
2018-01-26 |
2019-08-01 |
Nurix Therapeutics, Inc. |
Inhibitors of cbl-b and methods of use thereof
|
|
JP7600123B2
(ja)
|
2018-10-15 |
2024-12-16 |
ニューリックス セラピューティクス，インコーポレイテッド |
ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
|
|
WO2020167518A1
(en)
|
2019-02-13 |
2020-08-20 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
EP3953346A1
(en)
|
2019-04-09 |
2022-02-16 |
Nurix Therapeutics, Inc. |
3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
|
|
EP3969447A1
(en)
|
2019-05-17 |
2022-03-23 |
Nurix Therapeutics, Inc. |
Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
|
|
MX2021015675A
(es)
|
2019-06-26 |
2022-02-03 |
Nurix Therapeutics Inc |
Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
|
|
WO2021021761A1
(en)
|
2019-07-30 |
2021-02-04 |
Nurix Therapeutics, Inc. |
Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
|
|
EP4034141A1
(en)
|
2019-09-24 |
2022-08-03 |
Nurix Therapeutics, Inc. |
Cbl inhibitors and compositions for expansion of immune cells
|
|
US20230024442A1
(en)
|
2019-11-08 |
2023-01-26 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for grading btk via ubiquitin proteosome pathway
|
|
US11820781B2
(en)
|
2019-12-04 |
2023-11-21 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
|
|
US12016860B2
(en)
|
2021-04-08 |
2024-06-25 |
Nurix Therapeutics, Inc. |
Combination therapies with Cbl-b inhibitor compounds
|
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|
|
WO2023205180A1
(en)
|
2022-04-19 |
2023-10-26 |
Nurix Therapeutics, Inc. |
Biomarkers for cbl, and compositions and methods for their use
|
|
WO2023250097A1
(en)
|
2022-06-22 |
2023-12-28 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds and antiemetic agents
|